MeiraGTx Holdings plc (MGTX) Stock

About MeiraGTx Holdings plc

MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.

MeiraGTx Holdings plc is led by CEO Alexandria Forbes, employs 375 people, headquartered in US, publicly traded since 2018.

MeiraGTx Holdings plc (MGTX) stock trades at $12.31 with a market capitalization of $1.14B. The stock is valued at a price-to-earnings (P/E) ratio of -7.95, price-to-book of -16.46, price-to-sales of 13.67. Over the past 52 weeks the stock has ranged between $6.62 and $15.35, and currently trades 19.8% below its 52-week high.

On profitability, MeiraGTx Holdings plc generates a return on equity (ROE) of 474.91% — well above the market average, a sign of a high-quality business, return on capital employed of -153.50%, an operating margin of -130.86%, a net profit margin of -151.12%.

Official website: www.meiragtx.com